Kyle Doherty


Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

June 24th 2022

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

Nivolumab/Ipilimumab and Nivolumab/Chemo Indications Enhance ESCC Treatment Landscape

June 15th 2022

The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.

Venetoclax Plus Obinutuzumab Confers Long-Term Survival Benefits in Unfit Patients With CLL

June 13th 2022

Venetoclax plus obinutuzumab remains an effective fixed-duration treatment option for patients with chronic lymphocytic leukemia and coexisting conditions, according to updated efficacy and safety data from the ongoing phase 3 CLL14 trial.

BRUIN CLL-313 Trial To Evaluate Pirtobrutinib in Untreated CLL/SLL

June 12th 2022

The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.

Epcoritamab Elicits Impressive Responses in Relapsed/Refractory LBCL

June 11th 2022

The first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab demonstrated deep and durable responses in patients with relapsed/refractory large B-cell lymphoma.

Epcoritamab Plus GemOX Exhibits Promising Early Efficacy in R/R DLCBL

June 10th 2022

Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.

BRUIN CLL-321 Aims to Expand BTK Inhibitor Options in CLL/SLL

June 8th 2022

The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.

Patritumab Deruxtecan Induces Clinical Activity in NSCLC Regardless of Identified Driver Genomic Alterations

June 6th 2022

Patritumab deruxtecan exhibited promising clinical activity in heavily pretreated patients with advanced non-small cell lung cancer without EGFR-activating mutations, including activity in patients with other identified driver genomic alterations.

Ifosfamide Improves Survival vs Topotecan/Cyclophosphamide in R/R Ewing Sarcoma

June 5th 2022

Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.

Palbociclib Plus Letrozole Misses OS End Point in ER+/HER2- Advanced Breast Cancer

June 4th 2022

First-line treatment with palbociclib plus letrozole did not elicit a significant benefit in overall survival compared with letrozole monotherapy in patients with estrogen receptor-positive/HER2-negative advanced breast cancer missing the secondary end point of the trial.

Galinpepimut-S Plus Pembrolizumab Displays Early Efficacy in WT1+ Ovarian Cancer

May 31st 2022

Galinpepimut-S in combination with the PD-1 inhibitor pembrolizumab elicited a clinical benefit in patients with Wilms’ tumor-1-positive relapsed/refractory platinum-resistant advanced metastatic ovarian cancer, according to top line-line data from a phase 1/2 trial (NCT03761914).

ESR1 Mutations Provide Window Into Breast Cancer Metastasis

May 27th 2022

Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.

Increased Investment in Public Welfare Improves OS for Black Patients with Cancer

May 26th 2022

Increased spending on state public welfare programs was associated with a higher 5-year overall survival rate among Black patients.

MDM2 Pulls Novel Treatments Into Focus for Underserved Liposarcoma Population

May 24th 2022

Amplification of murine double minute 2 represents a promising target to access the so-called cellular gatekeeper p53 protein in human cancers.

Innovations in Patient-Reported Outcomes Lead to Better Care

May 20th 2022

For decades in cancer care, the compiling of patient-reported outcomes was limited to simple standardized questionnaires completed with pen and paper.

Pembrolizumab Monotherapy Adds Option in MSI-H/dMMR Endometrial Cancer

May 18th 2022

The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

TROP-2, Nectin-4 Are Highly Expressed in Urothelial, Variant Histology Bladder Cancer

May 16th 2022

TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in urothelial cancer and variant histology bladder cancer.

IS-002 Improves Prostate Cancer Visualization Prior to Robotic Prostatectomy

May 16th 2022

The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.

Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma

May 14th 2022

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

Ovarian Suppression with GnRH Agonists Can Aid Fertility Preservation in Breast Cancer

May 12th 2022

Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.